GI
GLUE icon

GAMMA Investing’s Monte Rosa Therapeutics GLUE Stock Holding History

GAMMA Investing’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$24.1K Sell
2,023
-91
-4% -$1.56K ﹤0.01% 2833
2026
Q2 		$51.2K Buy
2,114
+86
+4% +$1.63K ﹤0.01% 2281
2026
Q1 		$33.4K Buy
2,028
+123
+6% +$2.35K ﹤0.01% 2445
2025
Q4 		$29.9K Buy
+1,905
New +$25.7K ﹤0.01% 2395
2025
Q3 		– Sell
-80
Closed -$361 – 3880
2025
Q2 		$361 Sell
80
-1,148
-93% -$5.12K ﹤0.01% 3676
2025
Q1 		$5.7K Sell
1,228
-4,693
-79% -$28.8K ﹤0.01% 3033
2024
Q4 		$41.1K Buy
5,921
+5,866
+10,665% +$44K ﹤0.01% 1814
2024
Q3 		$292 Buy
55
+3
+6% +$15 ﹤0.01% 3459
2024
Q2 		$194 Hold
52
– – ﹤0.01% 3345
2024
Q1 		$367 Buy
+52
New +$308 ﹤0.01% 3149

Other funds holding GLUE

PP
Paladin Partners Hartland, Wisconsin $162M AUM 13.31% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's GLUE Position: Q3 2026 in Review

GAMMA Investing reduced its Monte Rosa Therapeutics (GLUE) stake by 4.3% in Q3 2026, selling an estimated $1.56K and leaving 2,023 shares worth $24.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2833.

GAMMA Investing first reported a position in GLUE in Q1 2024 and has held it in 10 quarters since. The position peaked at $51.2K in Q2 2026. 3 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

  • GAMMA Investing held 2,023 shares of Monte Rosa Therapeutics worth $24.1K as of Q3 2026.
  • GAMMA Investing sold 91 Monte Rosa Therapeutics shares in Q3 2026, an estimated $1.56K.
  • Monte Rosa Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2833 holding.
  • GAMMA Investing first reported a position in Monte Rosa Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • GAMMA Investing's Monte Rosa Therapeutics position peaked at $51.2K in Q2 2026.
  • 3 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.